Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 16, 2023 (4 years ago)

Doxazosin Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52

Affected NDC 51655-0109-52

Compare with the code on your package — it is the most precise check available.

Drug: Doxazosin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Doxazosin
NDC 51655-0109
MESYLATE 4 mg/1 Tablet
Oral
Northwind Health Company, LLC Rx
Recalling firm
Northwind Pharmaceuticals LLC
NDC code
51655-109-52
Origin
IN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0550-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Doxazosin recalls

See all
Class III · Low risk

Doxazosin Tablets

Tablets/Capsules Imprinted with Wrong ID

Ongoing Labeling / mix-up Unichem Pharmaceuticals USA Inc. NDC 29300-353-10 D-0306-2026
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Terminated Impurity / degradation Viatris Inc NDC 58151-078-93 D-0204-2025
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Terminated Impurity / degradation Viatris Inc NDC 58151-079-93 D-0203-2025
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2080-10 D-0603-2024
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2040-10 D-0602-2024

Other recalls by Northwind Pharmaceuticals LLC

All 2023 recalls
Class II · Moderate risk

Sulfamethoxazole and Trimethoprim Tablets

Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Northwind Pharmaceuticals LLC NDC 51655-307-87 D-0654-2025
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-487-52 D-0554-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-473-87 D-0553-2023